Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable...
Main Authors: | Faleck, D.M (Author), Harris, J.P (Author), Postow, M.A (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis Infliximab induce respuesta clínica, endoscópica e histológica en la colitis ulcerosa refractaria
by: F. Bermejo, et al.
Published: (2004-02-01) -
Promising effect of infliximab on the extent of involvement in ulcerative colitis
by: Peyman Adibi, et al.
Published: (2011-01-01) -
Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab
by: A. López San Román, et al.
Published: (2004-06-01) -
A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients
by: Alejandro Pérez-Pitarch, et al.
Published: (2015-03-01) -
The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
by: Hyun Il Seo, et al.
Published: (2014-07-01)